An ophthalmic medical solution to be used in the treatment or prophylaxis of glaucoma comprising a compound of piridilaminoacético acid represented by the formula (1): ** ** Formula wherein each of R1, R2 and R3 represents independently an atom hydrogen or an alkyl group C1-C6, Y represents a bicyclic ring heteroaromatic or Q1-Q2 group, each of which may be substituted by one or more groups selected from the group consisting of a halogen atom, an alkyl group C1-C6 alkyl, a C1-C6 halogen, a C1-C6 alkoxyl group, an alkoxyl group C1-C6 halogen and a C1-C6 alkylthio group, where Q1 represents an arylene group or a heteroarylene group of 5 to 6-membered , Q2 represents an aromatic group or a heterocyclic ring group of 5 to 6 members, each of which may be substituted by one or more groups selected from the group consisting of a halogen atom, a hydroxyl group, C1-C6 alkyl, a C1-C6 halogen, a C1-C6 alkoxyl group and an alkoxy group C1-C6 halogen, Z represents an aromatic group or a heteroaromatic ring of 5 to 6 members, each of which can be substituted by one or more groups selected from the group consisting of a halogen atom, a C1-C6, an alkyl group C1-C6 halogen, an alkoxy group C1-C6 alkoxy C1-C6 halogen, or a salt pharmaceutically acceptable thereof as effective ingredient, and wherein the solution is placed in the eye.Una solución oftálmica médica a ser utilizada en el tratamiento o profilaxis de glaucoma que comprende un compuesto de ácido piridilaminoacético representado por la fórmula (1): **Fórmula** en donde cada uno de R1, R2 y R3 representa en forma independiente un átomo de hidrógeno o un grupo alquilo C1- C6, Y representa un grupo anular heteroaromático bicíclico o un grupo Q1-Q2, cada uno de los cuales puede encontrarse sustituido por uno o más grupos seleccionados del grupo que consiste en un átomo halógeno, un grupo alquilo C1-C6, un grupo alquilo C1-C6 halógeno, un grupo alcoxilo C1-C6, un grupo alcoxilo C1-C6 halógeno y un grupo alquiltio C1-C6, en donde
